Evidence map›Paper›PMID 38926365›Full record

ArticleNature communications2024

METTL3-mediated chromatin contacts promote stress granule phase separation through metabolic reprogramming during senescence.

Chen Wang, Hideki Tanizawa, Connor Hill, Aaron Havas, Qiang Zhang, Liping Liao, Xue Hao, Xue Lei, Lu Wang, Hao Nie and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Role of Stress Granules in Cardiovascular Diseases.Reviews in cardiovascular medicine · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. METTL3-mediated mActa biochimica et biophysica Sinica · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chen WangDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
Hideki TanizawaInstitute of Molecular Biology, University of Oregon, Eugene, OR, 97403, USA.
Connor HillGene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, 19104, USA.
Aaron HavasSanford Burnham Prebys Medical Discovery Institute, San Diego, CA, USA.
Qiang ZhangGene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, 19104, USA.
Liping LiaoDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
Xue HaoDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0003-4138-1447
Xue LeiSanford Burnham Prebys Medical Discovery Institute, San Diego, CA, USA.
Lu WangPenn Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Hao NieDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
Yuan QiDepartment of Bioinformatics & Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.ORCID 0000-0001-9718-7593
Bin TianGene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, 19104, USA.ORCID 0000-0001-8903-8256
Alessandro GardiniGene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, 19104, USA.ORCID 0000-0003-0413-2855
Andrew V KossenkovImmunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Aaron GoldmanMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0001-7605-9592
Shelley L BergerPenn Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-5398-4400
Ken-Ichi NomaInstitute of Molecular Biology, University of Oregon, Eugene, OR, 97403, USA.ORCID 0000-0002-5187-6788
Peter D AdamsSanford Burnham Prebys Medical Discovery Institute, San Diego, CA, USA.ORCID 0000-0002-0684-1770
Rugang ZhangDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA. rzhang11@mdanderson.org.ORCID 0000-0002-7255-2360

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
STRUCTURAL BASIS FOR EPIGENETICS IN AGING AND LONGEVITYP01AG031862 · NIA · WISTAR INSTITUTE · PI MARMORSTEIN, RONEN · 2008 to 2022
$28.3M
National Metabolomics Data Repository - nextgen Metabolomics WorkbenchU2CDK119886 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2018 to 2021
$12.7M
Role of BRCA1 Pathway in Regulating Oncogene-Induced SenescenceR01CA160331 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2012 to 2021
$4.0M
Biomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2020 to 2024
$3.2M
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancerR01CA276569 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Rugang Zhang · 2023 to 2026
$2.1M
Regulation of gene expression by alternative polyadenylationR35GM153277 · NIGMS · WISTAR INSTITUTE · PI BIN TIAN · 2024 to 2026
$2.0M
Integrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelR50CA211199 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2016 to 2026
$1.6M
Regulation and Functions of 3'UTRs in Cellular StressR01GM129069 · NIGMS · WISTAR INSTITUTE · PI TIAN, BIN · 2018 to 2021
$1.5M
Mechanisms of enhancer regulation in aging and age-related diseasesR00AG065500 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI WANG, LU · 2023 to 2025
$742k
NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA160331NCI NIH HHS R01 CA276569NIA NIH HHS P01 AG031862NIA NIH HHS R00 AG065500NIDDK NIH HHS U2C DK119886NIGMS NIH HHS R01 GM129069NIGMS NIH HHS R35 GM153277NIH HHS OT2 OD030544U.S. Department of Health & Human Services | National Institutes of Health (NIH) P01AG031862U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA160331U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA276569
6 · The paper itself

Abstract

METTL3 is the catalytic subunit of the methyltransferase complex, which mediates m

Indexed as

Cellular SenescenceChromatinMethyltransferasesStress GranulesAdenosineHEK293 CellsHexokinaseHumansMetabolic ReprogrammingPhase SeparationRNA, MessengerAdenosineChromatinHexokinaseMethyltransferasesMETTL3 protein, humanRNA, Messenger

Identifiers

PMID38926365
PMCPMC11208586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.